Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ. Sclafani F, et al. J Natl Cancer Inst. 2015 Sep 23;107(12):djv258. doi: 10.1093/jnci/djv258. Print 2015 Dec. J Natl Cancer Inst. 2015. PMID: 26405092 Clinical Trial.
Cetuximab or bevacizumab in metastatic colorectal cancer?
Sclafani F, Cunningham D. Sclafani F, et al. Lancet Oncol. 2014 Sep;15(10):1040-1. doi: 10.1016/S1470-2045(14)70360-2. Epub 2014 Jul 31. Lancet Oncol. 2014. PMID: 25088941 No abstract available.
Response.
Sclafani F, Cunningham D, Peckitt C, Watkins D. Sclafani F, et al. J Natl Cancer Inst. 2016 Jan 11;108(3):djv405. doi: 10.1093/jnci/djv405. Print 2016 Mar. J Natl Cancer Inst. 2016. PMID: 26754850 No abstract available.
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ. Sclafani F, et al. Int J Cancer. 2017 Jan 15;140(2):431-439. doi: 10.1002/ijc.30453. Epub 2016 Oct 17. Int J Cancer. 2017. PMID: 27681944 Free article. Clinical Trial.
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Gonzalez de Castro D, Tabernero J, Glimelius B, Cervantes A, Eltahir Z, Oates J, Chau I. Sclafani F, et al. Ann Oncol. 2013 Dec;24(12):3123-8. doi: 10.1093/annonc/mdt408. Epub 2013 Oct 20. Ann Oncol. 2013. PMID: 24146218 Free article. Clinical Trial.
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N. Sclafani F, et al. Ann Oncol. 2015 Sep;26(9):1936-1941. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10. Ann Oncol. 2015. PMID: 26162609 Free PMC article. Clinical Trial.
FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.
Sclafani F, Gonzalez de Castro D, Cunningham D, Hulkki Wilson S, Peckitt C, Capdevila J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Begum R, Thomas J, Oates J, Chau I. Sclafani F, et al. Clin Cancer Res. 2014 Sep 1;20(17):4511-9. doi: 10.1158/1078-0432.CCR-14-0674. Epub 2014 Jul 1. Clin Cancer Res. 2014. PMID: 24987061 Clinical Trial.
113 results